MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, SGP had $80,090K increase in cash & cash equivalents over the period. -$33,490K in free cash flow.

Cash Flow Overview

Change in Cash
$80,090K
Free Cash flow
-$33,490K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Gross proceeds from issuance of ...
    • Redemptions of short-term invest...
    • Stock-based compensation
    • Others
Negative Cash Flow Breakdown
    • Purchases of short-term investme...
    • Repurchases of common stock
    • Payments for deferred offering c...
    • Others

Cash Flow
2025-12-31
Net loss
-39,869
Depreciation expense
612
Loss on disposal of property and equipment
-5
Non-cash lease expense
383
Gain on lease termination
518
Stock-based compensation
2,786
Change in fair value of redeemable convertible preferred stock tranche liability
1,526
Interest receivable
74
Other receivables
8
Prepaid expenses and other current assets
186
Other non-current assets
38
Accounts payable
549
Payroll-related accruals
900
Accrued expenses and other current liabilities
1,672
Lease liability
-441
Net cash used in operating activities
-32,701
Property and equipment
789
Purchases of short-term investments
17,001
Redemptions of short-term investments
5,996
Net cash (used in) provided by investing activities
-11,794
Proceeds from exercise of stock options
170
Repurchases of common stock
1,450
Gross proceeds from issuance of redeemable convertible preferred stock
127,336
Issuance costs of redeemable convertible preferred stock
288
Payments for deferred offering cost
1,183
Net cash provided by financing activities
124,585
Net increase in cash and cash equivalents
80,090
Cash and cash equivalents, beginning of year
16,268
Cash and cash equivalents, end of year
96,358
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Gross proceeds fromissuance of redeemable...$127,336K Proceeds from exercise ofstock options$170K Net cash provided byfinancing activities$124,585K Canceled cashflow$2,921K Net increase in cashand cash...$80,090K Canceled cashflow$44,495K Repurchases of common stock$1,450K Payments for deferredoffering cost$1,183K Issuance costs ofredeemable convertible...$288K Stock-based compensation$2,786K Accrued expenses andother current...$1,672K Change in fair value ofredeemable convertible...$1,526K Payroll-related accruals$900K Depreciation expense$612K Accounts payable$549K Non-cash lease expense$383K Loss on disposal ofproperty and equipment-$5K Redemptions of short-terminvestments$5,996K Net cash used inoperating activities-$32,701K Net cash (used in)provided by investing...-$11,794K Canceled cashflow$8,433K Canceled cashflow$5,996K Net loss-$39,869K Purchases of short-terminvestments$17,001K Gain on leasetermination$518K Lease liability-$441K Prepaid expenses andother current assets$186K Interest receivable$74K Other non-currentassets$38K Other receivables$8K Property and equipment$789K

SpyGlass Pharma, Inc. (SGP)

SpyGlass Pharma, Inc. (SGP)